Therapeutic Areas |
Psychiatry
Psychiatry
|
Latuda® (lurasidone HCI)
Psychiatry
|
Lunesta® (eszopiclone)
Psychiatry
|
Resources
Psychiatry
|
Disease State
Psychiatry
|
Disease State
|
Bipolar Depression
Psychiatry
|
Disease State
|
Schizophrenia
Psychiatry
|
Disease State
|
General Psychiatry
|
Publications
Psychiatry
|
Latuda® (lurasidone HCI)
|
Publications
Therapeutic Areas |
Neurology
Neurology
|
Aptiom® (eslicarbazepine acetate)
Neurology
|
Kynmobi™ (apomorphine hydrochloride)
Neurology
|
Resources
Neurology
|
Disease State
Neurology
|
Disease State
|
Parkinson's
Neurology
|
Disease State
|
Epilepsy
Neurology
|
Disease State
|
General Neurology
|
Publications
|
Publications
Therapeutic Areas |
Respiratory
Respiratory
|
Brovana® (arformoterol tartrate)
Respiratory
|
Lonhala® Magnair® (glycopyrrolate)
Respiratory
|
Xopenex HFA® (levalbuterol tartrate)
Respiratory
|
Resources
Respiratory
|
Disease State
Respiratory
|
Disease State
|
COPD
Respiratory
|
Disease State
|
General Respiratory
|
Publications
|
Publications
|
Publications
Submit Medical Inquiry
Request Field Medical
Resources
Adverse Event & Product Complaint Reporting
Pipeline
| SEP-363856
| SEP-363856 | Schizophrenia 4 Weeks
| SEP-363856 | Schizophrenia 26 Weeks
| SEP-363856 | PD Psychosis 6 Weeks
| SEP-4199
| SEP-4199 | 6 Week
Search Medical Information
Scientific Conferences
Search Medical Information
Psychiatry
Neurology
Respiratory
Home
Therapeutic Area
Psychiatry
Neurology
Respiratory
submit medical inquiry
request field medical
resources
adverse event & product complaint reporting
pipeline
back
Pipeline
click to view
SEP-363856
Schizophrenia
click to view
SEP-363856
Parkinson's disease psychosis
click to view
SEP-4199
Bipolar Depression
DSP-3905
Neuropathic pain
DSP-6745
Parkinson's disease psychosis
SEP-378608
Bipolar disorder
SEP-378614
Treatment resistant depression
SEP-380135
Agitation in Alzheimer's disease
These are investigational compounds whose safety and efficacy have not been reviewed or approved by the FDA
opt-in to communications from Sunovion
First Name
Last Name
Email
Phone Number
By checking this box, I agree and acknowledge that the information I’ve provided voluntarily will be used only by Sunovion and its contracted third-parties to contact me regarding my request. I understand that Sunovion will not sell or transfer my name to any third party for their marketing use. Please see the most recent version of our privacy notice, which may change from time to time.
Submit
contact us
Sunovion Pharmaceuticals Inc.
Medical Information
84 Waterford Drive
Marlborough, MA 01752
1-800-739-0565
minfo@sunovion.com
Global Medical Information
UNITED KINGDOM
Sunovion Pharmaceuticals Europe Ltd.
Medical Information
+44(0) 1423 852857
medinfo@sunovion.eu
CANADA
Sunovion Pharmaceuticals Canada Inc.
Medical Information
1-866-260-6291, option 2
sunovionmedinfo@solutionsinhealth.com
OTHER COUNTRIES
Sunovion Pharmaceuticals Inc.
Medical Information
800-739-0565
minfo@sunovion.com
For information about the collection and use of your personal information, please visit
www.sunovion.com/HCPprivacynotice
THANK YOU
Thank you for rating SunovionMedical.com
close
HCP/FDM Confirmation
Please confirm below to continue
I confirm that I am a Health Care Professional (HCP) practicing in the United States, or acting on behalf of an HCP
OR
I am a Formulary Decision Maker (FDM) and/or working on behalf of a public or private payer organization to review scientific information to make drug or device selection or acquisition, formulary management, or coverage and reimbursement decisions on a population basis.
YOU ARE NOW LEAVING SUNOVIONMEDICAL.COM
You are now leaving SunovionMedical.com
ok
cancel
back
are registered trademarks of Sumitomo Dainippon Pharma Co., Ltd.
